atorvastatin has been researched along with Chronic Disease in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (49.02) | 29.6817 |
| 2010's | 24 (47.06) | 24.3611 |
| 2020's | 2 (3.92) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, Z; Ma, T; Sun, D; Zhang, F; Zhang, Y | 1 |
| Blom, D; Guler, R; Günther, G; Kengne, AP; Motaung, B; Mukasa, S; Nepolo, E; Ozturk, M; Sabeel, S; Schacht, C; Sliwa, K; Thienemann, F; Wilkinson, RJ | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| Huang, J; Li, HH; Liang, FL; Mo, JL; Ou, BQ; Peng, Y; Zhou, Z | 1 |
| Hu, Y; Jin, M; Li, GC; Liu, HG; Liu, W; Ren, J; You, ZX | 1 |
| Bible, PW; Guo, F; Guo, M; Liu, J; Shi, D; Shi, J; Tian, Y; Wang, C; Wang, P; Wei, L; Yang, M | 1 |
| Attwa, EM; El-Korashi, LA; Mohamed, NA; Soliman, MH | 1 |
| Esmaillzadeh, A; Larijani, B; Milajerdi, A | 1 |
| Cui, W; Hu, HJ; Liu, DM; Liu, J; Wang, Q; Zhang, HL; Zhang, YN | 1 |
| Dai, XP; Li, XR; Wang, JQ; Wang, Z; Wu, GR | 1 |
| Chang, CH; Chang, YC; Chuang, LM; Lee, YC; Lin, JW; Liu, YC | 1 |
| Bianchi, C; Chu, LM; Dalal, RS; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Chen, JY; Chu, LW; Wu, BN; Wu, PC | 1 |
| Deng, Y; Guo, XL; Liu, HG; Pan, YY; Yuan, X; Zhu, D | 1 |
| de Oliveira, RM; Ferreira, ED; Godinho, J; Milani, H; Previdelli, IS; Ribeiro, MH; Zaghi, GG | 1 |
| An, LP; An, SK; Fu, SY; Wei, XH; Wu, HA | 1 |
| Acharya, AB; Surve, SM; Thakur, SL | 1 |
| Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K | 1 |
| Chaudhuri, R; Donnelly, I; Hothersall, EJ; Lafferty, J; McInnes, I; McMahon, AD; McSharry, C; Meiklejohn, J; Sattar, N; Thomson, NC; Weir, CJ; Wood, S | 1 |
| Campistol Plana, JM | 1 |
| Cui, W; Liu, F; Lu, JC; Pei, WN; Xie, RQ; Yang, C | 1 |
| Dahlof, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Anker, SD; Földes, G; von Haehling, S | 1 |
| Chou, SY; Fitzgerald, JP; Franco, I; Gulmi, FA; Kim, H; Mooppan, UM; Saini, R | 1 |
| Bonkovsky, HL; Russo, MW; Scobey, M | 1 |
| Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C | 1 |
| Aslani, A; Cheng, KK; Gharravi, M; Khoshnia, M; Larijani, B; Malekzadeh, F; Malekzadeh, R; Marshall, T; Nateghi, A; Pourshams, A; Rastegarpanah, M; Salahi, R; Semnani, S; Thomas, GN | 1 |
| Chaiyakunapruk, N; Cheewasithirungrueng, N; Dilokthornsakul, P; Jeanpeerapong, N; Nimpitakpong, P; Srisupha-olarn, W; Thanarungroj, A | 1 |
| Chaitman, BR; Goldberger, JJ; Messig, M; Schwartz, GG | 1 |
| Kiiakbaev, GK; Kobalava, ZhD; Moiseev, VS; Ozova, EM | 1 |
| Akilli, H; Alihanoglu, Y; Altunkeser, BB; Aribas, A; Ayhan, S; Can, I; Demir, K; Koc, F; Vatankulu, MA | 1 |
| Takagi, H; Umemoto, T | 1 |
| Bahrami, A; Farid Hosseini, R; Jabbari, F; Pezeshkpoor, F; Rafatpanah, H; Sadri, H; Shakerian, B; Yousefzadeh, H; Zamani, MA; Zandkarimi, MR | 1 |
| Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM | 1 |
| Gersh, BJ; Raco, DL; Rihal, CS; Yusuf, S | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
| Florkowski, CM; Frampton, CM; George, PM; Molyneux, SL; Scott, RS; Strey, CH; Young, JM | 1 |
| Chin, H; Denu-Ciocca, CJ; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS; Pieper, JA | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC | 1 |
| van der Harst, P; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Kiberd, BA | 1 |
| Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A | 1 |
| Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J | 1 |
| Chou, SY; Gulmi, FA; Kim, H; Michli, E; Mooppan, UM | 1 |
| Gu, M; Liu, M; Wu, Y; Yin, C; Zhang, W; Zhu, P | 1 |
| Campese, VM; Park, J | 1 |
| Paraskevas, KI | 1 |
| Alcaino, H; Bustos, C; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; Mellado, R; Miranda, R; Verdejo, HE; Vukasovic, JL | 1 |
| Blauw, GJ; de Man, FH; Jukema, JW; Smelt, AH; van der Laarse, A; Weverling-Rijnsburger, AW | 1 |
| Anliker, MD; Wüthrich, B | 1 |
7 review(s) available for atorvastatin and Chronic Disease
| Article | Year |
|---|---|
Statins influence biomarkers of low grade inflammation in apparently healthy people or patients with chronic diseases: A systematic review and meta-analysis of randomized clinical trials.
Topics: Adult; Atorvastatin; Biomarkers; C-Reactive Protein; Chronic Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin | 2019 |
Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies.
Topics: Atorvastatin; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MEDLINE; Prospective Studies; Pyrroles | 2014 |
[Chronic transplant nephropathy].
Topics: Animals; Atorvastatin; Atrophy; Biopsy; Chronic Disease; Complement C4b; Heptanoic Acids; Humans; Kidney Transplantation; Kidney Tubules; Nephritis, Interstitial; Peptide Fragments; Postoperative Complications; Pyridoxamine; Pyrroles; Rats; Risk Factors; Terminology as Topic; Transplants | 2008 |
Drug-induced liver injury associated with statins.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Autoimmunity; Biomarkers; Biopsy; Chemical and Drug Induced Liver Injury; Chronic Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Liver; Liver Diseases; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Assessment; Treatment Outcome; Young Adult | 2009 |
A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease.
Topics: Atorvastatin; Chronic Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic | 2011 |
Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Chronic Disease; Coronary Artery Bypass; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2003 |
Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Kidney Diseases; Lipids; Peritoneal Dialysis; Pyrroles; Risk Assessment; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
15 trial(s) available for atorvastatin and Chronic Disease
| Article | Year |
|---|---|
Role of Atorvastatin in Treatment of Chronic Spontaneous Urticaria Patients: A Controlled Clinical Trial.
Topics: Atorvastatin; Basophils; Chronic Disease; Histamine; Histamine Antagonists; Humans; Phosphoric Diester Hydrolases; Pyrophosphatases; Skin Tests; Urticaria | 2018 |
Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Asthmatic Agents; Asthma; Atorvastatin; Biomarkers; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Sputum; Vital Capacity | 2008 |
Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Electrocardiography; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long QT Syndrome; Pyrroles; Treatment Outcome; Ventricular Function, Left | 2010 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Disease; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Young Adult | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heptanoic Acids; Humans; Hydrochlorothiazide; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Tablets | 2010 |
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Atrial Fibrillation; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Retrospective Studies; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2011 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvastatin; Blood Pressure; C-Reactive Protein; Carbazoles; Carvedilol; Chronic Disease; Drug Therapy, Combination; Elasticity; Female; Heart Failure; Heptanoic Acids; Humans; Interleukin-6; Male; Metoprolol; Middle Aged; Myocardial Ischemia; Propanolamines; Pyrroles; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Resistance | 2011 |
Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy.
Topics: Analysis of Variance; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Chronic Disease; Electric Countershock; Female; Fibrinogen; Health Status Indicators; Heptanoic Acids; Humans; Leukocyte Count; Male; Middle Aged; Pyrroles; Secondary Prevention; Time Factors; Warfarin | 2011 |
Efficacy of atorvastatin and antihistamines in comparison with antihistamines plus placebo in the treatment of chronic idiopathic urticaria: a controlled clinical trial.
Topics: Adolescent; Adult; Atorvastatin; Biomarkers; Chronic Disease; Cytokines; Drug Therapy, Combination; Female; Heptanoic Acids; Histamine Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Iran; Male; Middle Aged; Pyrroles; Severity of Illness Index; Single-Blind Method; Time Factors; Treatment Outcome; Urticaria; Young Adult | 2012 |
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles | 2003 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Coenzymes; Cross-Over Studies; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ubiquinone; Vascular Resistance; Vasodilation | 2005 |
Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Chronic Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Particle Size; Phenotype; Pilot Projects; Pyrroles; Renal Dialysis; Risk Factors; Triglycerides | 2005 |
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator | 2006 |
Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin.
Topics: Acetylcholine; Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Chronic Disease; Endothelium, Vascular; Free Radical Scavengers; Heptanoic Acids; Humans; Hypertriglyceridemia; Injections, Intravenous; Male; Middle Aged; Nitroprusside; Pyrroles; Serotonin; Triglycerides; Vasodilation; Vasodilator Agents | 2000 |
29 other study(ies) available for atorvastatin and Chronic Disease
| Article | Year |
|---|---|
Atorvastatin alleviates left ventricular remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho kinase signaling pathway.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Chronic Disease; Echocardiography; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Male; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; rho GTP-Binding Proteins; rho-Associated Kinases; Signal Transduction; Ventricular Remodeling | 2020 |
Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases.
Topics: Adult; Atorvastatin; Chronic Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Simvastatin; Systematic Reviews as Topic | 2020 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
Synergistic Effect of Atorvastatin and Folic Acid on Cardiac Function and Ventricular Remodeling in Chronic Heart Failure Patients with Hyperhomocysteinemia.
Topics: Aged; Aged, 80 and over; Atorvastatin; China; Chronic Disease; Female; Folic Acid; Heart Failure; Heart Function Tests; Humans; Hyperhomocysteinemia; Male; Middle Aged; Ventricular Remodeling | 2018 |
Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCε Pathway.
Topics: Animals; Atorvastatin; Cardiomegaly; Cardiotonic Agents; Cell Line; Chronic Disease; Hypoxia; MicroRNAs; Myocardium; Myocytes, Cardiac; Protein Kinase C-epsilon; Rats; Signal Transduction; Up-Regulation | 2018 |
Panax Quinquefolium Saponins Attenuate Myocardial Dysfunction Induced by Chronic Ischemia.
Topics: Animals; Arterioles; Atorvastatin; Chromatography, High Pressure Liquid; Chronic Disease; Coronary Stenosis; Down-Regulation; Echocardiography; Glucose; Heart; Mass Spectrometry; Myocardial Infarction; Myocardium; Positron-Emission Tomography; Proteome; Proteomics; Saponins; Swine; Up-Regulation; Ventricular Function | 2018 |
Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2 in the genomic pathway.
Topics: Aldosterone; Animals; Atorvastatin; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Chronic Disease; DNA; Fibroblasts; Flow Cytometry; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2013 |
Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Chronic Disease; Cohort Studies; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Diseases; Male; Middle Aged; Pyrroles; Risk; Severity of Illness Index; Taiwan; Time Factors | 2015 |
Atorvastatin regulates apoptosis in chronically ischemic myocardium.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Chronic Disease; Disease Models, Animal; Gene Expression Regulation, Developmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Neovascularization, Pathologic; Pyrroles; Swine; Swine, Miniature | 2015 |
Atorvastatin prevents neuroinflammation in chronic constriction injury rats through nuclear NFκB downregulation in the dorsal root ganglion and spinal cord.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cell Nucleus; Chronic Disease; Constriction, Pathologic; Disease Models, Animal; Down-Regulation; Ganglia, Spinal; Hyperalgesia; Male; Microglia; Neuralgia; Neuroimmunomodulation; NF-kappa B; Rats, Sprague-Dawley; Spinal Cord; Time Factors; Treatment Outcome | 2015 |
Efficacy of atorvastatin on hippocampal neuronal damage caused by chronic intermittent hypoxia: Involving TLR4 and its downstream signaling pathway.
Topics: Animals; Atorvastatin; Chronic Disease; Disease Models, Animal; Hippocampus; Hypoxia; Interleukin-1beta; Male; Malondialdehyde; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Neurons; Neuroprotective Agents; Random Allocation; Signal Transduction; Sleep Apnea, Obstructive; Superoxide Dismutase; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2015 |
Robust and enduring atorvastatin-mediated memory recovery following the 4-vessel occlusion/internal carotid artery model of chronic cerebral hypoperfusion in middle-aged rats.
Topics: Aging; Amnesia, Retrograde; Animals; Atorvastatin; Brain; Cerebrovascular Disorders; Chronic Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Maze Learning; Memory; Nootropic Agents; Pyramidal Cells; Rats, Wistar; Treatment Outcome | 2016 |
Atorvastatin improves cardiac function of rats with chronic cardiac failure via inhibiting Rac1/P47phox/P67phox-mediated ROS release.
Topics: Animals; Atorvastatin; Chronic Disease; Heart Failure; Hemodynamics; Humans; Male; NADH, NADPH Oxidoreductases; NADPH Oxidases; rac1 GTP-Binding Protein; Rats; Rats, Wistar; Reactive Oxygen Species | 2015 |
Efficacy of subgingivally delivered atorvastatin and simvastatin as an adjunct to scaling and root planing.
Topics: Administration, Buccal; Adult; Atorvastatin; Case-Control Studies; Chronic Disease; Dental Scaling; Gels; Gingival Crevicular Fluid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1alpha; Middle Aged; Periodontitis; Root Planing; Simvastatin; Treatment Outcome | 2015 |
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor | 2008 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Heart Failure; Heptanoic Acids; Humans; Pyrroles; Signal Transduction; Th1 Cells; Th2 Cells | 2009 |
Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases.
Topics: Animals; Atorvastatin; Chronic Disease; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Tubules; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2009 |
Estimation of financial burden due to oversupply of medications for chronic diseases.
Topics: Aged; Atorvastatin; Chronic Disease; Clopidogrel; Drug Costs; Female; Heptanoic Acids; Hospitals, University; Humans; Male; Middle Aged; Pharmaceutical Preparations; Phenylcarbamates; Pyrroles; Retrospective Studies; Rivastigmine; Rosiglitazone; Tetrazoles; Thailand; Thiazolidinediones; Ticlopidine; Valine; Valsartan | 2012 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Chronic Disease; Creatinine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerulonephritis; Heptanoic Acids; Humans; Insulin; Insulin, Long-Acting; Insulin, Regular, Human; Lipoproteins; Male; Middle Aged; Proteinuria; Pyrroles; Retrospective Studies; Serum Albumin; Serum Albumin, Human; Time Factors; Treatment Outcome | 2005 |
Statins and autonomic function in chronic heart failure.
Topics: Atorvastatin; Autonomic Nervous System; Chronic Disease; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
Topics: Atorvastatin; Cardiovascular Diseases; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure | 2006 |
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain | 2006 |
Atorvastatin preserves renal function in chronic complete unilateral ureteral obstruction.
Topics: Animals; Atorvastatin; Chronic Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2007 |
Protective effects of atorvastatin on chronic allograft nephropathy in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chemokines; Chronic Disease; Cyclosporine; Cytokines; Drug Therapy, Combination; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Graft Rejection; Heptanoic Acids; Immunosuppressive Agents; Kidney Transplantation; Male; Monocytes; Proteinuria; Pyrroles; Rats; Rats, Inbred F344; Rats, Inbred Lew; T-Lymphocytes; Transplantation, Homologous | 2007 |
HMG-CoA reductase inhibitors and renal function.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Coronary Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lipoproteins, LDL; Pyrroles | 2007 |
Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
Topics: Aged; Atorvastatin; Biomarkers; Brachial Artery; Chronic Disease; Endothelium, Vascular; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Time Factors; Vasodilation; Walking | 2008 |
Chronic urticaria to atorvastatin.
Topics: Atorvastatin; Chronic Disease; Drug Hypersensitivity; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Urticaria | 2002 |